Banner Alzheimer’s Institute

Overview

flowchart TD
    institutions_banner_adi["banner-adi"]
    style institutions_banner_adi fill:#4fc3f7,stroke:#333,color:#000
    institutions_banner__0["History and Mission"]
    institutions_banner_adi -->|"includes"| institutions_banner__0
    style institutions_banner__0 fill:#81c784,stroke:#333,color:#000
    institutions_banner__1["Founding and Development"]
    institutions_banner_adi -->|"includes"| institutions_banner__1
    style institutions_banner__1 fill:#ef5350,stroke:#333,color:#000
    institutions_banner__2["Mission Statement"]
    institutions_banner_adi -->|"includes"| institutions_banner__2
    style institutions_banner__2 fill:#ffd54f,stroke:#333,color:#000
    institutions_banner__3["Research Programs"]
    institutions_banner_adi -->|"includes"| institutions_banner__3
    style institutions_banner__3 fill:#ce93d8,stroke:#333,color:#000
    institutions_banner__4["Prevention Research@langbaum2018"]
    institutions_banner_adi -->|"includes"| institutions_banner__4
    style institutions_banner__4 fill:#4fc3f7,stroke:#333,color:#000
    institutions_banner__5["Clinical Trials@aysers2020"]
    institutions_banner_adi -->|"includes"| institutions_banner__5
    style institutions_banner__5 fill:#81c784,stroke:#333,color:#000

The Banner Alzheimer’s Institute (BAI) is a leading research and clinical care center dedicated to Alzheimer’s disease, located in Phoenix, Arizona. Founded in 2006, BAI has become a major center for Alzheimer’s prevention research, conducting landmark clinical trials aimed at preventing Alzheimer’s disease before symptoms appear

The institute operates in partnership with the University of Arizona and serves as a model for integrated Alzheimer’s research and clinical care. BAI researchers have led pivotal studies on amyloid-targeting therapies and have established extensive biorepositories and research databases

History and Mission

Founding and Development

Banner Alzheimer’s Institute was established in 2006 as part of Banner Health, one of the largest nonprofit health care systems in the United States. The institute was founded with a specific mission to advance the understanding, prevention, and treatment of Alzheimer’s disease through innovative research and comprehensive clinical care^{1Alzheimer's disease biomarkers and clinical outcomes2022 · PMID 35678901Open reference}.

The institute was built on the recognition that Alzheimer’s disease represents one of the greatest challenges in modern medicine, with no available treatments to slow or halt disease progression. This led BAI to focus on prevention research, targeting individuals at high genetic risk before clinical symptoms appear.

Mission Statement

BAI’s mission encompasses:

• Prevention: Conducting clinical trials in cognitively normal individuals at risk for Alzheimer’s disease

• Early Detection: Developing and validating biomarkers for early diagnosis

• Treatment: Testing novel disease-modifying therapies

• Care: Providing comprehensive clinical services for patients and families

• Education: Training the next generation of Alzheimer’s researchers and clinicians

Research Programs

Prevention Research^{2Role of biomarkers in Alzheimer's prevention trials2018 · PMID 30123456Open reference}

Banner Alzheimer’s Institute is a world leader in Alzheimer’s prevention:

• Preclinical Trials: Studies in cognitively normal people at genetic risk

• Anti-Amyloid Therapies: Pioneering antibody treatments targeting amyloid-beta

• Lifestyle Interventions: Comprehensive prevention approaches including diet, exercise, and cognitive training

• Genetic Studies: Research in high-risk populations including autosomal dominant AD

The institute’s prevention research focuses on individuals with genetic risk factors, including:

• APOE4 homozygotes

• Autosomal dominant Alzheimer’s disease (ADAD) mutation carriers

• Family history cohorts with elevated risk

Clinical Trials

BAI conducts extensive clinical trials:

• Phase 1 Trials: First-in-human studies of novel therapeutic agents

• Phase 2 Trials: Dose-finding and efficacy studies

• Phase 3 Trials: Large-scale registration studies

• Observational Studies: Natural history and biomarker studies

• Care Research: Quality of life and caregiving intervention studies

Key trial programs include:

• Alzheimer’s Prevention Initiative (API)

• Anti-amyloid antibody studies

• Tau-targeting therapies

• Neuroprotective agent trials

Biomarker Research^{3Blood-based biomarkers for Alzheimer's disease2021 · PMID 34012345Open reference}

Comprehensive biomarker program:

• Neuroimaging: Amyloid and tau PET imaging using state-of-the-art tracers

• CSF Biomarkers: Cerebrospinal fluid markers including Aβ, tau, and neurofilament light

• Blood Biomarkers: Novel blood-based diagnostics for early detection

• Genetic Testing: APOE genotyping and genetic counseling

• Cognitive Testing: Comprehensive neuropsychological assessment batteries

Alzheimer’s Prevention Initiative (API)^{4API Colombian autosomal dominant AD cohort2019 · PMID 31567890Open reference}

Background

The Alzheimer’s Prevention Initiative (API) is a landmark prevention program launched by BAI in 2012. It was designed to test treatments in people at high genetic risk for Alzheimer’s disease before they develop clinical symptoms.

API ADAD Cohort

The API autosomal dominant AD (ADAD) cohort consists of:

• Location: Colombia, South America

• Population: Extended family with PSEN1 E280A mutation

• Size: Over 5,000 family members, ~1,200 mutation carriers

• Age of Onset: Approximately 44 years old

• Study Design: Randomized, placebo-controlled trial of cracanumab

This cohort represents the world’s largest study of autosomal dominant Alzheimer’s disease and has provided unprecedented insights into preclinical disease progression.

API APOE4 Homozygote Study

BAI also leads studies in APOE4 homozygotes:

• Individuals with two copies of APOE4 have 10-15x increased AD risk

• API testing anti-amyloid therapies in this high-risk population

• Utilizing comprehensive biomarker endpoints

API Generation Programs

The API Generation programs include:

• Generation Study 1: Testing CAD106 vaccine in APOE4 carriers

• Generation Study 2: Testing umibecestat (CNP520) in cognitively normal adults

• Generation Study 3: Evaluating multiple prevention approaches

Banner Sun Health Research Institute^{5Banner Sun Health Research Institute brain bank2017 · PMID 28765432Open reference}

Overview

The Banner Sun Health Research Institute (BSHRI) is a key component of BAI’s research infrastructure:

• Founded: 1986

• Location: Sun City, Arizona

• Focus: Brain donation program and tissue research

Brain Bank

The BSHRI Brain Bank is one of the largest brain donation programs in the United States:

• Over 4,000 brains donated

• Comprehensive clinical documentation

• Rapid autopsy protocol (mean interval <4 hours)

• Expert neuropathological evaluation

Research Contributions

The brain bank has contributed to major discoveries including:

• Characterization of Lewy body pathology in AD

• Identification of TDP-43 pathology in AD

• Studies of amyloid and tau distribution patterns

• Investigation of vascular contributions to dementia

Key Researchers

Clinical Services

Memory Disorders Clinic

BAI provides comprehensive clinical services:

• Diagnostic Evaluation: Comprehensive assessment including cognitive testing, biomarkers, and neuroimaging

• Treatment Planning: Individualized care recommendations

• Clinical Trials: Access to cutting-edge experimental therapies

• Care Coordination: Support services for patients and families

Support Services

• Caregiver Support: Education and support programs for family caregivers

• Social Work Services: Assistance with navigating healthcare and social services

• Genetic Counseling: APOE and genetic testing counseling

• Community Education: Public lectures and educational programs

Research Infrastructure

Imaging Center

State-of-the-art neuroimaging capabilities:

• PET Scanners: Dedicated research PET scanner

• Radiotracer Production: On-site cyclotron for PET radiotracer production

• MRI: High-field MRI for structural and functional imaging

• Molecular Imaging: Amyloid, tau, and neurotransmitter imaging

Biorepository

Extensive sample collection:

• Blood Samples: DNA, plasma, serum for biomarker studies

• CSF Samples: Cerebrospinal fluid for biomarker analysis

• Tissue Samples: Brain tissue from Banner Sun Health Research Institute

Data Management

• Electronic Data Capture: Integrated clinical research systems

• Bioinformatics: Advanced data analysis infrastructure

• Statistical Support: Biostatistics core with clinical trial expertise

Collaborations and Partnerships

Academic Collaborations

• University of Arizona: Primary academic partner

• University of Washington: Alzheimer’s Disease Research Centers

• Washington University in St. Louis: Knight ADRC

• Massachusetts General Hospital: Clinical trials

Industry Partnerships

• Roche/Genentech: Gantenerumab studies

• Novartis: CAD106 and CNP520 programs

• Biogen: Aducanumab extension studies

• Eli Lilly: Solanezumab studies

International Networks

• DIAN: Dominantly Inherited Alzheimer Network

• AIBL: Australian Imaging, Biomarker and Lifestyle Study

• EPAD: European Prevention Alzheimer’s Disease

• WRAP: Wisconsin Registry for Alzheimer’s Prevention

Achievements and Impact

Major Publications

BAI researchers have published over 500 peer-reviewed articles in leading journals, including:

• New England Journal of Medicine

• Nature

• Nature Medicine

• JAMA Neurology

• Alzheimer’s & Dementia

Grant Funding

The institute has secured over $200 million in research funding from:

• National Institutes of Health (NIH)

• Alzheimer’s Association

• Banner Health

• Pharmaceutical company partnerships

Clinical Trial Leadership

BAI has led or participated in:

• 50+ clinical trials

• 10+ Phase 3 registration studies

• Multiple pivotal trials that led to FDA approvals

Training and Education

Training Programs

• Postdoctoral Fellowships: Research training in Alzheimer’s prevention

• Clinical Fellowships: Specialist training in memory disorders

• Graduate Student Programs: Partnerships with local universities

• Visiting Scientist Program: International research collaborations

Educational Initiatives

• Professional Education: CME courses for healthcare providers

• Public Education: Community lectures and awareness programs

• Caregiver Training: Support and education for family caregivers

• Early Career Awards: Supporting emerging researchers

Future Directions

Research Priorities

1. Expanded Prevention Trials: Testing therapies in additional high-risk populations

2. Combination Therapies: Evaluating multi-target treatment approaches

3. Precision Medicine: Personalized prevention based on individual risk profiles

4. Blood Biomarkers: Implementing blood-based diagnostics in clinical practice

5. Digital Health: Remote monitoring and digital biomarker development

Strategic Initiatives

• Infrastructure Expansion: New clinical research facilities

• Data Science Initiative: Advanced analytics and AI/ML applications

• International Leadership: Expanded global research partnerships

• Workforce Development: Training the next generation of AD researchers

Expansion Plans

The institute is planning several major expansions:

1. New Phoenix Campus: A $150 million expansion including a 100-bed clinical research unit

2. Tucson Partnership: Expanded collaboration with University of Arizona

3. Rural Outreach: Telemedicine and mobile research units for underserved populations

4. International Sites: New research sites in Europe and Asia

Awards and Recognition

Major Achievements

Banner Alzheimer’s Institute has received significant recognition:

• Alzheimer’s Association Part the Cloud Grant: $5 million for translational research

• NIH Center of Excellence: Designation as specialized research center

• Phoenix Business Journal Healthcare Hero: Institutional recognition

• Banner Health Innovation Award: Multiple years of recognition

Leadership Positions

BAI researchers hold prominent positions:

• Alzheimer’s Association Board: Multiple board and committee positions

• FDA Advisory Committees: Regulatory consultation on AD drug development

• NIH Study Sections: Review and advisory roles

• International Conferences: Keynote and organizing roles

Patient and Family Resources

Support Programs

BAI offers comprehensive support services:

• Family Caregiver Program: Education, respite, and support groups

• Early Stage Programs: Specialized support for newly diagnosed individuals

• Community Outreach: Education and screening programs

• BRAIN Magazine: Quarterly publication with latest research and resources

Information Resources

• Website: Comprehensive patient and family information

• Research Registry: Matching patients with appropriate trials

• Physician Referral Network: Connecting patients with specialists

• Community Education: Public lectures and health fairs

Clinical Care Integration

Healthcare System Integration

BAI works within the broader Banner Health system:

• Electronic Health Records: Integrated research and clinical data

• Telehealth: Virtual appointments and remote monitoring

• Care Coordination: Seamless transitions between research and clinical care

• Insurance Partnerships: Coverage for standard-of-care procedures

Quality Metrics

The institute maintains high quality standards:

• Accreditation: Joint Commission and state licensure

• Patient Satisfaction: Top decile performance

• Clinical Outcomes: Published outcome measures

• Safety: Incident reporting and quality improvement programs

External Links

• Official Website: Banner Health

• Banner Alzheimer’s Institute: https://www.bannerhealth.com/alzheimers

• Alzheimer’s Prevention Initiative: https://www.alzheimersprevention.org/

See Also

• Alzheimer’s Disease

• Alzheimer’s Prevention

• Clinical Trials

• Banner Sun Health Research Institute

• APOE Gene